Home > Insider Trading > Filing (0000950170-24-029165)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1708493	Harpoon Therapeutics Inc.	HARP	Pharmaceutical Preparations (2834)	NJ

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
64978	Merck Sharp & Dohme Llc	126 East Lincoln Avenue Rahway NJ 07065		No	No	No	No
310158	Merck & Co., Inc.	126 East Lincoln Avenue Rahway NJ 07065		No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, Par Value $0.0001	Acquisiton	2024-03-11	21,397,205	$23.00	1,000	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnote

Footnotes

Pursuant to the Agreement and Plan of Merger, dated as of January 7, 2024 by and among Merck Sharp & Dohme LLC, a wholly owned subsidiary of Merck & Co. Inc. ("Parent"), Hawaii Merger Sub, Inc., a wholly owned subsidiary of Merck Sharp & Dohme LLC ("Merger Sub"), and Harpoon Therapeutics, Inc. ("Harpoon"), Merger Sub merged with and into Harpoon (the "Merger") on March 11, 2024. Upon completion of the Merger, each share of common stock of Harpoon that was issued and outstanding immediately prior to the effective time of the Merger was cancelled, and each share of common stock of Merger Sub was converted into one share of common stock of the surviving corporation.
(Continued from footnote 1) Consequently, upon the consummation of the Merger on March 11, 2024, Parent became the direct beneficial owner of 1,000 shares of common stock of the surviving corporation, representing 100% of the issued and outstanding shares of common stock of the surviving corporation. Merck & Co., Inc. is the indirect beneficial owner of such shares.